Wells Fargo & Company Cuts Bath & Body Works (NYSE:BBWI) Price Target to $33.00

Bath & Body Works (NYSE:BBWIFree Report) had its target price lowered by Wells Fargo & Company from $44.00 to $33.00 in a research report released on Monday morning, MarketBeat reports. The firm currently has an overweight rating on the stock.

BBWI has been the topic of several other reports. Morgan Stanley reduced their price objective on Bath & Body Works from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, September 12th. Citigroup reduced their price target on Bath & Body Works from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, August 19th. Barclays reduced their price target on Bath & Body Works from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Monday, October 20th. Weiss Ratings restated a “hold (c-)” rating on shares of Bath & Body Works in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group reduced their price target on Bath & Body Works from $32.00 to $28.50 and set a “hold” rating on the stock in a research report on Monday, October 13th. Eleven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Bath & Body Works currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.39.

View Our Latest Report on Bath & Body Works

Bath & Body Works Trading Down 4.9%

Shares of Bath & Body Works stock opened at $24.82 on Monday. The firm has a market capitalization of $5.12 billion, a PE ratio of 7.37, a price-to-earnings-growth ratio of 0.90 and a beta of 1.52. The business’s 50-day moving average price is $27.26 and its 200-day moving average price is $29.03. Bath & Body Works has a 12 month low of $24.81 and a 12 month high of $41.87.

Bath & Body Works (NYSE:BBWIGet Free Report) last announced its quarterly earnings data on Thursday, August 28th. The company reported $0.37 EPS for the quarter, meeting the consensus estimate of $0.37. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.55 billion. Bath & Body Works had a negative return on equity of 48.43% and a net margin of 9.88%.The company’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the company earned $0.37 EPS. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. As a group, analysts predict that Bath & Body Works will post 3.3 earnings per share for the current fiscal year.

Bath & Body Works Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 5th. Shareholders of record on Friday, August 22nd were issued a $0.20 dividend. The ex-dividend date was Friday, August 22nd. This represents a $0.80 annualized dividend and a yield of 3.2%. Bath & Body Works’s dividend payout ratio (DPR) is 23.74%.

Institutional Investors Weigh In On Bath & Body Works

Several institutional investors and hedge funds have recently bought and sold shares of BBWI. First Horizon Corp purchased a new stake in Bath & Body Works in the 3rd quarter worth approximately $29,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in Bath & Body Works in the 2nd quarter worth approximately $33,000. SVB Wealth LLC purchased a new stake in Bath & Body Works in the 1st quarter worth approximately $35,000. Geneos Wealth Management Inc. lifted its holdings in Bath & Body Works by 217.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after buying an additional 801 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in Bath & Body Works by 63.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,241 shares of the company’s stock worth $37,000 after buying an additional 481 shares during the period. Hedge funds and other institutional investors own 95.14% of the company’s stock.

About Bath & Body Works

(Get Free Report)

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.

Further Reading

Analyst Recommendations for Bath & Body Works (NYSE:BBWI)

Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.